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Clinical manifestations of D. polylepis toxins
D. polylepis
The snakebite challenge
With an annual 150,000 deaths and countless amputations and disfigurements,
snakebite envenoming is an ever-present threat in many parts of the rural tropical
world1. In sub-Saharan Africa, only 1-2% of victims are treated with antivenom2,
which is currently based on animal-derived antibodies. Due to their heterologous
origin, antivenoms often provoke serious side effects in human recipients, such as
serum sickness and anaphylaxis, which in some cases leads to death3.
Selection of high-affinity human scFvs by phage display
Future: Human recombinant oligoclonal antivenoms
The aim of this research is to enable the production of modern, fully recombinant,
oligoclonal antivenoms consisting of specifically selected human IgG antibodies with
proven specificity against medically relevant D. polylepis toxins. It is the hope that
results obtained during this study will help pave the way for cost-effective recombinant
antivenoms with better safety and efficacy for treatment of snakebite envenoming in
sub-Saharan Africa.
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D. polylepis venom composition and actions
The potency of the venom of D.
polylepis, is derived from the
synergism between type I and II α-
neurotoxins and dendrotoxins,
which target nicotinic acetylcholine
receptors and potassium channels,
respectively, causing involuntary
muscle contractions, flaccid
paralysis, and death4.
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